These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 33716107)
1. Existing and emerging therapies for the treatment of familial hypercholesterolemia. Rosenson RS J Lipid Res; 2021; 62():100060. PubMed ID: 33716107 [TBL] [Abstract][Full Text] [Related]
2. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. Raal F; Panz V; Immelman A; Pilcher G J Am Heart Assoc; 2013 Apr; 2(2):e000028. PubMed ID: 23537802 [TBL] [Abstract][Full Text] [Related]
3. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy. Hartgers ML; Besseling J; Stroes ES; Wittekoek J; Rutten JHW; de Graaf J; Visseren FLJ; Imholz BPM; Roeters van Lennep JE; Huijgen R; Kastelein JJP; Hovingh GK J Clin Lipidol; 2018; 12(4):972-980.e1. PubMed ID: 29934068 [TBL] [Abstract][Full Text] [Related]
4. Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries. Arca M; Celant S; Olimpieri PP; Colatrella A; Tomassini L; D'Erasmo L; Averna M; Zambon A; Catapano AL; Russo P J Am Heart Assoc; 2023 Nov; 12(21):e026550. PubMed ID: 37850449 [TBL] [Abstract][Full Text] [Related]
5. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management. Miname MH; Santos RD Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498 [TBL] [Abstract][Full Text] [Related]
6. Familial hypercholesterolemia treatments: Guidelines and new therapies. Raal FJ; Hovingh GK; Catapano AL Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089 [TBL] [Abstract][Full Text] [Related]
7. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008 [TBL] [Abstract][Full Text] [Related]
11. Novel treatment options for the management of heterozygous familial hypercholesterolemia. Polychronopoulos G; Tziomalos K Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604 [TBL] [Abstract][Full Text] [Related]
12. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604 [TBL] [Abstract][Full Text] [Related]
13. Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1). Gaudet D; Durst R; Lepor N; Bakker-Arkema R; Bisgaier C; Masson L; Golden L; Kastelein JJ; Hegele RA; Stein E Am J Cardiol; 2019 Dec; 124(12):1876-1880. PubMed ID: 31685212 [TBL] [Abstract][Full Text] [Related]
14. Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia. Tomlinson B; Patil NG; Fok M; Lam CWK Endocrinol Metab (Seoul); 2021 Apr; 36(2):279-295. PubMed ID: 33866776 [TBL] [Abstract][Full Text] [Related]
15. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Robinson JG J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430 [TBL] [Abstract][Full Text] [Related]
16. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy. Vishwanath R; Hemphill LC J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684 [TBL] [Abstract][Full Text] [Related]
17. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry. Vrablik M; Raslová K; Vohnout B; Blaha V; Satny M; Kyselak O; Vaclova M; Urbanek R; Maskova J; Soska V; Freiberger T Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071 [TBL] [Abstract][Full Text] [Related]